Financial

News

AZ's Q3 sales reach record $15bn, but it holds guidance

AstraZeneca takes another step forwards towards its target of growing revenues to $80bn by 2030, as quarterly sales top $15bn for the first time.

News

Novo Nordisk's new chief executive Mike Doustdar

Novo Nordisk cuts guidance again on weaker GLP-1 growth

Novo Nordisk's first set of financial results under new CEO Mike Doustdar continues the theme of lower growth expectations for the company this year.

News

MSD still seeking deals 'with urgency' after Verona takeover

MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions.

News

Lilly climbs on stellar GLP-1 drug sales gain

Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.

News

Specialty meds lift GSK's outlook in Walmsley's swan song

Emma Walmsley's last set of financial results as GSK's chief executive has gone swimmingly, allowing the company to raise its 2025 forecasts.

News

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.

AZ's Q3 sales reach record $15bn, but it holds guidance

Novo Nordisk cuts guidance again on weaker GLP-1 growth

MSD still seeking deals 'with urgency' after Verona takeover

Lilly climbs on stellar GLP-1 drug sales gain

Specialty meds lift GSK's outlook in Walmsley's swan song

Falling flu vaccine sales in US stall CSL's Seqirus spinout

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Financial

Editor's Picks